Deacetylase Inhibitor News and Research

RSS
Epigenetic therapy holds promise for cancer management

Epigenetic therapy holds promise for cancer management

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

LLS collaborates with Shape Pharmaceuticals to advance treatment for CTCL

LLS collaborates with Shape Pharmaceuticals to advance treatment for CTCL

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Cancer research at Georgia Tech: Report

Cancer research at Georgia Tech: Report

Second-quarter fiscal 2010 results announced by Pharmacyclics

Second-quarter fiscal 2010 results announced by Pharmacyclics

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Embryonic stem cells raise hope of cellular replacement therapy for liver failure

Embryonic stem cells raise hope of cellular replacement therapy for liver failure

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

FDA accepts IND for Arno Therapeutics' Pan-DAC / Akt inhibitor, AR-42

FDA accepts IND for Arno Therapeutics' Pan-DAC / Akt inhibitor, AR-42

CuraGen announces results with Belinostat and Velafermin

CuraGen announces results with Belinostat and Velafermin